Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 1,016 matching trials from the live ClinicalTrials.gov search.
Filters: "chemoradiation" Clear all
Not yet recruiting Phase 2 Interventional

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

NCT07346196
View directory record Official record
Conditions
Squamous Cell Carcinoma
Interventions
Cemiplimab, Fianlimab, Carboplatin, Paclitaxel, Radiation
Drug · Radiation
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 10, 2026, 2:41 PM EDT
Active, not recruiting Phase 1 Interventional

Dose Escalation of Neoadjuvant Proton Beam Radiotherapy With Concurrent Chemotherapy in Locally Advanced Esophageal Cancer

NCT02213497
View directory record Official record
Conditions
Esophageal Cancer
Interventions
18F-FDG (Fluorodeoxyglucose) PET, Carboplatin, Paclitaxel
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Feasibility Study of a Nurse Intervention to Impact Mucositis Severity and Prevent Dehydration

NCT03416582
View directory record Official record
Conditions
Lung Cancer, Mucositis Oral, Dehydration, Head and Neck Cancer
Interventions
Symptom Management Education and Nurse Coaching, Drinks Diary
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2019 · Synced Oct 10, 2026, 2:41 PM EDT
Active, not recruiting Not applicable Interventional

Diffusion MRI for Head and Neck Cancer

NCT04251481
View directory record Official record
Conditions
Head Cancer Neck
Interventions
PET/MRI with FDG, MRI scan without contrast, MRI with gadolinium
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 10, 2026, 2:41 PM EDT
Completed No phase listed Observational

Assessment of Symptom-Related Cytokines in Lung and Gastrointestinal (GI) Cancer Patients

NCT00502502
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer, Lung Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

NCT00923195
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide, Radiation, Aldesleukin, Fludarabine, Cyclophosphamide, Anti-gp 100:154 TCR PBL, Anti-MART-1 F5 TCR PBL
Drug · Procedure · Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Oct 10, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

NCT00369551
View directory record Official record
Conditions
Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
3-dimensional conformal radiation therapy, paclitaxel, bevacizumab, carboplatin, laboratory biomarker analysis
Radiation · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Oct 10, 2026, 2:41 PM EDT
Completed No phase listed Observational

Predicting Tolerance to Radiation Therapy in Older Adults With Cancer

NCT01752751
View directory record Official record
Conditions
Pre-treatment Loss of Independent Activities of Daily Living
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 10, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional

Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer

NCT00614601
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
HyperAcute(R)-Pancreatic Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 10, 2026, 2:41 PM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Therapy for Localized Rectal Adenocarcinoma

NCT04418895
View directory record Official record
Conditions
Rectal Adenocarcinoma
Interventions
Chemoradiation, short course radiation therapy, mFOLFOX6, CAPOX, fluoropyrimidine +/- oxaliplatin
Other · Radiation · Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 10, 2026, 2:41 PM EDT
Terminated Early Phase 1 Interventional

A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer

NCT04630353
View directory record Official record
Conditions
HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer
Interventions
HB-201 IV
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 10, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

NCT07022483
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Trastuzumab Deruxtecan, Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older · Female only
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
10
States / cities
Fort Lauderdale, Florida • Miami, Florida • Miami Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 10, 2026, 2:41 PM EDT
Recruiting Phase 3 Interventional

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

NCT07566156
View directory record Official record
Conditions
Urothelial Cancer, Urinary Bladder Neoplasms
Interventions
Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
Drug · Radiation
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
15
States / cities
Santa Barbara, California • Aurora, Colorado • Newark, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 10, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy

NCT02392377
View directory record Official record
Conditions
Stage IB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma
Interventions
Paclitaxel, Carboplatin, Oxaliplatin, Leucovorin Calcium, Fluorouracil, Radiation Therapy, Therapeutic Conventional Surgery, Laboratory Biomarker Analysis
Drug · Radiation · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2018 · Synced Oct 10, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

Weekly Oxaliplatin and Gemcitabine for Recurrent or Metastatic Head and Neck Cancer

NCT00256295
View directory record Official record
Conditions
Cancer of the Head and Neck
Interventions
Gemcitabine, Oxaliplatin
Drug
Lead sponsor
Sai-Hong Ignatius Ou
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2017 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

NCT00554463
View directory record Official record
Conditions
Lung Cancer
Interventions
Filgrastim, Pegfilgrastim, Etoposide, Cisplatin, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
14
States / cities
Gainesville, Florida • Miami Beach, Florida • Lexington, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 10, 2026, 2:41 PM EDT
Completed No phase listed Observational

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

NCT04027543
View directory record Official record
Conditions
Radiotherapy Side Effect, Chemotherapy Effect, Oesophageal Carcinoma, Effect of Drugs, Safety Issues
Interventions
Neoadjuvant chemoradiotherapy, Oesophagectomy, Neoadjuvant chemotherapy
Combination Product · Procedure · Drug
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Other
Eligibility
18 Years to 80 Years
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

NCT00321685
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7
Interventions
Bevacizumab, Capecitabine, Fluorouracil, Leucovorin Calcium, Oxaliplatin, Radiation Therapy, Therapeutic Conventional Surgery
Biological · Drug · Radiation + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
107
States / cities
Birmingham, Alabama • New Britain, Connecticut • Atlanta, Georgia + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 10, 2026, 2:41 PM EDT
Not listed Phase 2 Interventional

Cetuximab, Cisplatin, and Radiotherapy in Women With Locally Advanced Cervical Carcinoma

NCT00292955
View directory record Official record
Conditions
Cancer of the Cervix
Interventions
Cetuximab
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
2
States / cities
St Louis, Missouri • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 30, 2011 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Early Phase 1 Interventional

MET-PET for Newly Diagnosed Glioblastoma

NCT01867593
View directory record Official record
Conditions
Glioblastoma
Interventions
C-11 methionine PET
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

NCT00137852
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Cisplatin, Irinotecan, Celecoxib, Radiation Therapy, Esophagectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 10, 2026, 2:41 PM EDT
Completed Phase 3 Interventional Results available

A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT02125461
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
MEDI4736, PLACEBO
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
60
States / cities
Chandler, Arizona • Goodyear, Arizona • Jonesboro, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2023 · Synced Oct 10, 2026, 2:41 PM EDT
Terminated Phase 1 Interventional

Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma

NCT03246113
View directory record Official record
Conditions
Glioblastoma
Interventions
Cannabis, Temozolomide, Radiation Therapy
Drug · Radiation
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 10, 2026, 2:41 PM EDT
Recruiting Phase 1 Interventional

A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies

NCT06719362
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
M3T01, Pembrolizumab, Chemoradiation, FOLFOX regimen
Drug · Radiation
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 10, 2026, 2:41 PM EDT